JP2007538009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007538009A5 JP2007538009A5 JP2007511527A JP2007511527A JP2007538009A5 JP 2007538009 A5 JP2007538009 A5 JP 2007538009A5 JP 2007511527 A JP2007511527 A JP 2007511527A JP 2007511527 A JP2007511527 A JP 2007511527A JP 2007538009 A5 JP2007538009 A5 JP 2007538009A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- phospholipase
- membered ring
- inhibitor
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C1C(*)C2C(*)C(*)C(*)C(*)C2C1* Chemical compound *C1C(*)C2C(*)C(*)C(*)C(*)C2C1* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/838,879 US20050244367A1 (en) | 2004-05-03 | 2004-05-03 | Phospholipase inhibitors localized in the gastrointestinal lumen |
| PCT/US2005/015416 WO2005112646A2 (en) | 2004-05-03 | 2005-05-03 | Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007538009A JP2007538009A (ja) | 2007-12-27 |
| JP2007538009A5 true JP2007538009A5 (cg-RX-API-DMAC7.html) | 2008-06-19 |
Family
ID=35187321
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511494A Pending JP2007536243A (ja) | 2004-05-03 | 2005-05-03 | ホスホリパーゼ−a2阻害薬を用いた、高コレステロール血症、高トリグリセリド血症、心臓血管疾患の治療 |
| JP2007511527A Pending JP2007538009A (ja) | 2004-05-03 | 2005-05-03 | インドールおよび関連化合物から成るホスホリパーゼ−a2阻害薬を用いた、食事関連疾患の治療 |
| JP2007511528A Pending JP2007536249A (ja) | 2004-05-03 | 2005-05-03 | 消化器官管腔集中性ホスホリパーゼ阻害薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511494A Pending JP2007536243A (ja) | 2004-05-03 | 2005-05-03 | ホスホリパーゼ−a2阻害薬を用いた、高コレステロール血症、高トリグリセリド血症、心臓血管疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511528A Pending JP2007536249A (ja) | 2004-05-03 | 2005-05-03 | 消化器官管腔集中性ホスホリパーゼ阻害薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20050244367A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1750699A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2007536243A (cg-RX-API-DMAC7.html) |
| CA (3) | CA2565384A1 (cg-RX-API-DMAC7.html) |
| WO (3) | WO2005112953A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008005661A (es) * | 2005-11-03 | 2008-12-15 | Ilypsa Inc | Inhibidores de fosfolipasa, que incluyen inhibidores de fosfolipasa multivalente, y uso de los mismos, que incluyen como inhibidores de fosfolipasa localizadas en el lumen. |
| EP1960356A2 (en) | 2005-11-03 | 2008-08-27 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
| WO2008055148A2 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Semi-solid formulations of phospholipase enzyme inhibitors |
| CL2007003143A1 (es) * | 2006-10-31 | 2008-01-25 | Wyeth Corp | Composicion farmaceutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepracion; y forma de dosificacion. |
| WO2009082491A1 (en) * | 2007-12-26 | 2009-07-02 | Alp Life Sciences, Llc | Nanovesontm: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases |
| US20090197955A1 (en) * | 2008-01-31 | 2009-08-06 | Monsanto Company | Methods of improving dha deposition and related function and/or development |
| EP3187182B1 (en) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| MX377553B (es) * | 2009-04-29 | 2025-03-10 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| BRPI1011883A2 (pt) | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| NZ599061A (en) | 2009-09-23 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| US9603826B2 (en) | 2012-06-29 | 2017-03-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| RU2015107019A (ru) | 2012-08-21 | 2016-10-10 | Эрделикс Инк. | Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| CN105392483B (zh) | 2013-04-12 | 2019-03-15 | 阿德利克斯公司 | 用于抑制磷酸盐转运的nhe3结合化合物和方法 |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| CN107684550B (zh) * | 2016-08-03 | 2020-04-10 | 徐天宏 | 糖尿病治疗产品及其制备与应用 |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| CN111386279A (zh) | 2017-08-04 | 2020-07-07 | 阿德利克斯股份有限公司 | 用于治疗高钾血症的甘草次酸衍生物 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| MA50490A (fr) | 2018-09-24 | 2020-09-02 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| JP7735185B2 (ja) | 2019-02-07 | 2025-09-08 | アルデリックス, インコーポレイテッド | 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体 |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
| CA3160676A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7017227A (cg-RX-API-DMAC7.html) * | 1969-12-27 | 1971-06-29 | ||
| US4211765A (en) * | 1971-10-12 | 1980-07-08 | Monsanto Company | Method for controlling obesity |
| US4432968A (en) * | 1980-10-20 | 1984-02-21 | The Dow Chemical Company | Weight control with fat imbibing polymers |
| US5274089A (en) * | 1985-10-18 | 1993-12-28 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US5196542A (en) * | 1985-10-18 | 1993-03-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| EP0243449A1 (en) * | 1985-10-18 | 1987-11-04 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US5145874A (en) * | 1985-10-18 | 1992-09-08 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US5373095A (en) * | 1985-10-18 | 1994-12-13 | The Upjohn Company | Steroid compounds |
| US5187299A (en) * | 1985-10-18 | 1993-02-16 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US4820714A (en) * | 1986-05-02 | 1989-04-11 | University Of Virginia Alumni Patents Foundation | Use of phospholipase inhibitors in the treatment of Clostridium difficile diarrhea |
| US5001234A (en) * | 1987-04-16 | 1991-03-19 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| IL84252A (en) * | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
| US5124334A (en) * | 1987-11-30 | 1992-06-23 | Du Pont Merck Pharmaceutical Company | Benzylalcohol phospholipase A2 inhibitors |
| US4948813A (en) * | 1987-11-30 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Benzylketone phospholipase A2 inhibitors |
| US5039706A (en) * | 1987-11-30 | 1991-08-13 | Du Pont Merck Pharmaceutical Company | Antiinflammatory PLA2 inhibitors |
| US5218124A (en) * | 1989-10-27 | 1993-06-08 | American Home Products Corporation | Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase |
| US5086067A (en) * | 1989-12-18 | 1992-02-04 | G. D. Searle & Co. | Ltb4 synthesis inhibitors |
| US5144045A (en) * | 1990-11-13 | 1992-09-01 | American Cyanamid Company | Phosphocholine derivative inhibitors of phospholipase A2 |
| US5298652A (en) * | 1992-12-08 | 1994-03-29 | Hoffmann-La Roche Inc. | N-substituted glycines, inhibitors of phospholipase A2 |
| HU213165B (en) * | 1993-05-11 | 1997-02-28 | Bot | Process to prepare biopolymers with detoxicating activity |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| GB9324409D0 (en) * | 1993-11-27 | 1994-01-12 | Smithkline Beecham Plc | Novel composition |
| EP1950200B1 (en) * | 1994-04-01 | 2012-01-11 | Eli Lilly And Company | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor |
| US5470882A (en) * | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
| US5578639A (en) * | 1994-07-01 | 1996-11-26 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| US5504073A (en) * | 1994-07-01 | 1996-04-02 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| JPH08268916A (ja) * | 1995-03-28 | 1996-10-15 | Dai Ichi Seiyaku Co Ltd | 微粒子性運搬体−薬物コンプレックス |
| JP3372408B2 (ja) * | 1995-09-21 | 2003-02-04 | 第一製薬株式会社 | 微粒子性運搬体・薬物−コンプレックス |
| CA2262847C (en) * | 1996-08-01 | 2007-06-05 | Merckle Gmbh | Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2 |
| US6630496B1 (en) * | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
| JP2000516958A (ja) * | 1996-08-26 | 2000-12-19 | ジェネティックス・インスチチュート・インコーポレーテッド | ホスホリパーゼ酵素の阻害剤 |
| US6423754B1 (en) * | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
| US6290947B1 (en) * | 1997-09-19 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin-binding agents |
| US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| US6299868B1 (en) * | 1999-07-14 | 2001-10-09 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| US6264937B1 (en) * | 1998-01-09 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| EE200000522A (et) * | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks |
| US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| WO2000010568A1 (en) * | 1998-08-24 | 2000-03-02 | Draheim Susan E | Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase a¿2? |
| AR022204A1 (es) * | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
| JP2002535288A (ja) * | 1999-01-22 | 2002-10-22 | ウンツァ ディ マリア カルメラ マラッツィータ エッセ.ア.エッセ. | リポタンパク質複合体およびそれらを含む組成物 |
| US7034006B2 (en) * | 2000-01-10 | 2006-04-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| US20020001614A1 (en) * | 2000-02-10 | 2002-01-03 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
| US6492550B2 (en) * | 2000-02-18 | 2002-12-10 | Bristol-Myers Squibb Company | Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors |
| US6908609B2 (en) * | 2000-11-20 | 2005-06-21 | Dow Global Technologies Inc. | In vivo use of water absorbent polymers |
| US6368842B1 (en) * | 2000-12-15 | 2002-04-09 | Pe Corporation (Ny) | Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| TWI314457B (cg-RX-API-DMAC7.html) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
| US6495596B1 (en) * | 2001-03-23 | 2002-12-17 | Biozibe Laboratories, Inc. | Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2 |
| HUP0402577A3 (en) * | 2001-12-03 | 2011-05-30 | Wyeth Corp | Indole derivatives as inhibitors of cytosolic phospholipase a2, process for producing them and pharmaceutical compositions containing them |
| US20030225011A1 (en) * | 2002-05-31 | 2003-12-04 | Samuel David | Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease |
| US6565896B1 (en) * | 2002-07-03 | 2003-05-20 | Vitacost.Com, Inc. | Cholesterol treatment formulation |
| WO2004060346A2 (en) * | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
-
2004
- 2004-05-03 US US10/838,879 patent/US20050244367A1/en not_active Abandoned
-
2005
- 2005-05-03 WO PCT/US2005/015281 patent/WO2005112953A2/en not_active Ceased
- 2005-05-03 JP JP2007511494A patent/JP2007536243A/ja active Pending
- 2005-05-03 US US11/579,253 patent/US20080021049A1/en not_active Abandoned
- 2005-05-03 EP EP05779544A patent/EP1750699A4/en not_active Withdrawn
- 2005-05-03 JP JP2007511527A patent/JP2007538009A/ja active Pending
- 2005-05-03 EP EP05779968A patent/EP1750730A4/en not_active Withdrawn
- 2005-05-03 WO PCT/US2005/015418 patent/WO2005107766A1/en not_active Ceased
- 2005-05-03 EP EP05741781A patent/EP1747003A4/en not_active Withdrawn
- 2005-05-03 CA CA002565384A patent/CA2565384A1/en not_active Abandoned
- 2005-05-03 CA CA002565416A patent/CA2565416A1/en not_active Abandoned
- 2005-05-03 JP JP2007511528A patent/JP2007536249A/ja active Pending
- 2005-05-03 US US11/579,251 patent/US20070292385A1/en not_active Abandoned
- 2005-05-03 WO PCT/US2005/015416 patent/WO2005112646A2/en not_active Ceased
- 2005-05-03 CA CA002565448A patent/CA2565448A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007536243A5 (cg-RX-API-DMAC7.html) | ||
| ES2954451T3 (es) | Composiciones y usos de derivados de amidina | |
| JP6941109B2 (ja) | Fxrアゴニストを使用するための方法 | |
| ES2981782T3 (es) | Composiciones y métodos para tratar la inflamación crónica y enfermedades inflamatorias | |
| JP2020073468A (ja) | 肝障害を処置するための1,3−ジフェニルプロパ−2−エン−1−オン誘導体の使用 | |
| US20040209891A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| US20140155485A1 (en) | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases | |
| JP2019511478A (ja) | Fxrアゴニストを使用するための方法 | |
| TW200927093A (en) | Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products | |
| ES2958524T3 (es) | Isomiosmina para uso en el tratamiento de enfermedades autoinmunes | |
| PT2282779E (pt) | Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular | |
| AU2014211715A1 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| BRPI0511327A (pt) | combinações de glicopirrolato e agonistas do adrenorreceptor beta2 | |
| BR112015015864B1 (pt) | Uso de uma composição farmacêutica no tratamento de uma condição de dor severa | |
| KR20080106455A (ko) | 대사장애의 조합치료 | |
| US20120172341A1 (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
| JP2010518029A5 (cg-RX-API-DMAC7.html) | ||
| JP6202633B2 (ja) | ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 | |
| US20240130994A1 (en) | Ionic liquid formulations for treating diabetes | |
| JP2008115167A (ja) | トラネキサム酸を含有する気道杯細胞過形成抑制剤 | |
| US11324743B2 (en) | Treatment for the non alcoholic steatohepatitis and fibrosis | |
| US20100137429A1 (en) | Composition for transdermal or transmucosal administration | |
| JP6153264B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 | |
| JP5997658B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 | |
| US20220183327A1 (en) | Taste-Masking Formulation For Ketone Body Compounds |